Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 4

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 4
---
Strom, a pooled, human umbilical cord mesenchymal
stem cell product to treat recessive dystrophic epidermolysis bullosa (“RDEB”), a pediatric orphan disease caused by mutations
in the COL7A1 gene that results in a debilitating disease of skin blistering, dysphagia and failure to thrive with chronic wound problems
that often results in fatal squamous cell carcinoma.

XPro for AD and TRD

XPro, targets AD and TRD.
XPro for AD has completed Phase I trials. Secondary end-points which include blood biomarker, neuroimaging and additional neuropsychiatric
end-points which should be available approximately one month following the announcement of the top-line data. Finally, several months
after all the data are analyzed, the Company plans an end-of-Phase II meeting with the U.S. Food and Drug Administration (“FDA”) to finalize plans for the pivotal Phase III
trial. XPro for treatment of AD may be eligible for one or both accelerated approval pathways. We expect to be eligible for “Break
Through” status after completion of the Phase II in 2025.

We expect to start a pivotal
global registration trial in patients with AD after the results of the Phase II trial have been analyzed and we have completed our end-of-phase
2 meetings with regulatory authorities.

We expect to initiate Phase
II trials of XPro for TRD in the second half of 2025.

CORDSTROM for RDEB

CORDStrom
is a patent-pending cell medicine comprising aseptic, allogeneic, pooled hucMSCs in suspension for injection or infusion, which are recognized
for their immunomodulatory, anti-inflammatory and wound healing properties with potential to treat a diverse set of diseases. The CORDStrom
platform leverages, among other things, proprietary screening, pooling and expansion techniques to create off-the-shelf, allogeneic, pooled
hucMSCs as medicines to treat complex inflammatory diseases. CORDStrom products are designed to provide high-quality, off-the-shelf, batch-to-batch
consistent, scalable, cGMP manufactured, potent cellular medicines that can be produced at low cost and with repeatable specification
independent of donor characteristics. Initially developed at the INKmune manufacturing facilities utilizing UK academic grant funding,
CORDStrom is a mesenchymal stromal cell (“MSC”) product platform that shows promise as a first systemic therapy for potentially
treating